The expansion of the trial sees the initiation of studies in two new centers; these are Princess Margaret Hospital in Toronto, Canada, and Jewish General Hospital in Montreal. These will add to studies already on-going in the US, Europe, and Canada.
The study, which was launched in May 2005 at the Ottawa Regional Cancer Centre, is designed to evaluate the anti-tumor activity and tolerability of repeated doses of ADH-1 on an every three-week schedule in patients whose tumors express the molecular target N-cadherin.
“We are building additional momentum in the development of our lead biotechnology compound, ADH-1, with the addition of two more sites to our Canadian phase II trial as planned. Altogether, our phase Ib/II and phase II studies will provide important information regarding the optimal dose, dose schedule and tumor types for future phase III ADH-1 trials,” said Dr William Peters, chairman and CEO of Adherex.
Global pharmaceutical company GlaxoSmithKline has demonstrated its interest in ADH-1 by acquiring an option to in-license the drug.